Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

Inclusion Criteria: * Male or female patients \>18 years of age with a diagnosis of type 2 diabetes (WHO criteria). * Patients must be on current stable antiglycaemic treatment with oral drugs (OAD) or insulin 4 weeks before start of study drug and throughout study duration. * Patients must be on stable antihypertensive treatment (must include renin-angiotensin system blocking treatment) 4 weeks before start of study drug and throughout study duration. * HbA1c \>7.5 % * Urinary albumin creatinine ratio (UACR) \> 30 mg/g (in ≥2 out 3 morning spot urine collections prior to randomisation). * eGFR ≥ 45 ml/min/1.73 m2 * Stable RAAS-blocking treatment (more than or equal to 4 weeks prior to visit 0) If not stable at visit 0, screening phase can be prolonged to 4 weeks. Exclusion Criteria: * Current treatment with loop diuretics * Current treatment with thiazolidinediones * Current treatment with dapagliflozin or other SGLT2 inhibitor * Ongoing cancer treatment * Patients on hypertension treatment who are is not on stable antihypertensive treatment (must include renin-angiotensin system blocking treatment) 4 weeks before start of study drug and throughout study duration * Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3x ULN * Total bilirubin \>2.0 mg/dL (34.2 µmol/L) * Positive serologic evidence of current infectious liver disease including, Hepatitis B surface antigen and antibody and Hepatitis C virus antibody * eGFR: \<45 mL/min (calculated by MDRD formula) * History of unstable or rapidly progressing renal disease * Volume depleted patients. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status * Recent Cardiovascular Events in a patient: 1\. Acute Coronary Syndrome (ACS) within 2 months prior to enrolment 2.Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment 3. Acute Stroke or TIA within two months prior to enrolment 4. Less than two months post coronary artery revascularization * Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure. Note: eligible patients with congestive heart failure, especially those who are on diuretic therapy, should have careful monitoring of their volume status throughout the study. * Pregnant or breastfeeding patients * Patients who, in the judgement of the investigator, may be at risk for dehydration